Selection Strategies and Practical Application of BRAF V600E-Mutated Non-Small Cell Lung Carcinoma.

ABSTRACT:

Purpose

The incidence of BRAF V600E mutation in non-small cell lung carcinoma (NSCLC) is lower than 2%, which poses difficulties in finding legitimate patients for targeted therapy. We investigated the predictive factors pertaining to BRAF V600E and the effectiveness of the VE1 antibody as a screening method for patient selection.

Materials and methods

The study was designed into two steps. In a first group, BRAF-mutated NSCLCs were identified from sequencing data to determine the features of BRAF V600E mutation. The results of the first group helped the collection of adenocarcinomas with a papillary or micropapillary pattern but without EGFR or ALK alterations as a second group so that the frequency of BRAF V600E mutation could be calculated. The sensitivity and specificity

SUBMITTER: Hwang I 

PROVIDER: S-EPMC9296927 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature